Literature DB >> 26045645

Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes.

Uche Anadu Ndefo, Nicole O Anidiobi, Efrah Basheer, Angie T Eaton.   

Abstract

Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes.

Entities:  

Year:  2015        PMID： 26045645      PMCID： PMC4450666     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

1.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

Authors:  David R Whiting; Leonor Guariguata; Clara Weil; Jonathan Shaw
Journal:  Diabetes Res Clin Pract       Date:  2011-11-12       Impact factor: 5.602

2.  Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Authors:  R Grempler; L Thomas; M Eckhardt; F Himmelsbach; A Sauer; D E Sharp; R A Bakker; M Mark; T Klein; P Eickelmann
Journal:  Diabetes Obes Metab       Date:  2011-11-13       Impact factor: 6.577

3.  Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Authors:  J Rosenstock; L J Seman; A Jelaska; S Hantel; S Pinnetti; T Hach; H J Woerle
Journal:  Diabetes Obes Metab       Date:  2013-08-22       Impact factor: 6.577

4.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

Authors:  Ele Ferrannini; Elza Muscelli; Silvia Frascerra; Simona Baldi; Andrea Mari; Tim Heise; Uli C Broedl; Hans-Juergen Woerle
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 5.  Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Authors:  George L Bakris; Vivian A Fonseca; Kumar Sharma; Ernest M Wright
Journal:  Kidney Int       Date:  2009-04-08       Impact factor: 10.612

6.  Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.

Authors:  T Heise; E Seewaldt-Becker; S Macha; S Hantel; S Pinnetti; L Seman; H J Woerle
Journal:  Diabetes Obes Metab       Date:  2013-02-17       Impact factor: 6.577

7.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

8.  Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).

Authors:  Bernard Zinman; Silvio E Inzucchi; John M Lachin; Christoph Wanner; Roberto Ferrari; David Fitchett; Erich Bluhmki; Stefan Hantel; Joan Kempthorne-Rawson; Jennifer Newman; Odd Erik Johansen; Hans-Juergen Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2014-06-19       Impact factor: 9.951
  8 in total
  14 in total

1.  Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats.

Authors:  Sanaa Ahmed; Mahmoud M El-Sayed; Mohamed A Kandeil; Marwa M Khalaf
Journal:  Saudi Pharm J       Date:  2022-03-16       Impact factor: 4.562

2.  The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways.

Authors:  Rabab M Amer; Amira Kamel Eltokhy; Rasha Osama Elesawy; Amany Nagy Barakat; Eman Basha; Omnia Safwat Eldeeb; Alshimaa Aboalsoud; Nancy Mohamed Elgharabawy; Radwa Ismail
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

3.  Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.

Authors:  Ahmad Haidar; Leif Erik Lovblom; Nancy Cardinez; Nikita Gouchie-Provencher; Andrej Orszag; Michael A Tsoukas; C Marcelo Falappa; Adnan Jafar; Milad Ghanbari; Devrim Eldelekli; Joanna Rutkowski; Jean-François Yale; Bruce A Perkins
Journal:  Nat Med       Date:  2022-05-12       Impact factor: 87.241

Review 4.  Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.

Authors:  Alberto Aimo; Michele Senni; Andrea Barison; Giorgia Panichella; Claudio Passino; Antoni Bayes-Genis; Michele Emdin
Journal:  Heart Fail Rev       Date:  2022-04-29       Impact factor: 4.654

5.  Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and "Sweet Pee Encephalopathy" in Perioperative Hospital Management.

Authors:  Christopher Mackintosh; Arti Tewari; Jason Siegel; R Doris Wang; William Freeman
Journal:  Neurohospitalist       Date:  2019-03-07

6.  The comparison of efficacy and safety between different doses of empagliflozin in insulin-treated type 1 diabetes mellitus patients: a systematic review and meta-analysis protocol.

Authors:  Sumanta Saha; Sujata Saha
Journal:  J Diabetes Metab Disord       Date:  2020-05-21

Review 7.  A systematic review and meta-analysis of randomized controlled trials, juxtaposing the control of glycemia and blood pressure between large dose empagliflozin and placebo among type 1 diabetes patients.

Authors:  Sumanta Saha; Sujata Saha
Journal:  Int J Health Sci (Qassim)       Date:  2020 Mar-Apr

Review 8.  Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury.

Authors:  Michał Wiciński; Eryk Wódkiewicz; Karol Górski; Maciej Walczak; Bartosz Malinowski
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-11

9.  The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial.

Authors:  Rana M ElDash; Mohamed A Raslan; Sara M Shaheen; Nagwa Ali Sabri
Journal:  F1000Res       Date:  2021-04-26

10.  Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians.

Authors:  Guodong Pan; Mandar Deshpande; Haiyan Pang; Suresh Selvaraj Palaniyandi
Journal:  Eur J Pharmacol       Date:  2018-09-19       Impact factor: 5.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.